Soleno Therapeutics, Inc. (SLNO) P/E Ratio History
Insufficient DataValuation data unavailable. · Data 2025–2026
Loading P/E history...
P/E Ratio Analysis
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SLNO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SLNO Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SLNO P/E vs Peers
Rare Disease Commercial Leaders peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 10.3Lowest | -Best | +68% | |
| $1B | 12.2 | -Best | +91% | |
| $9B | 41.2 | -Best | +128% | |
| $6B | 118.8 | -Best | +2886%Best | |
| $515B | 49.9 | -Best | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SLNO Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $33.48 | $1.77 | 19.0x | -83% |
| FY2025 Q4 | Dec 31 2025 | $46.30 | $0.23 | 204.2x | +83% |
Average P/E for displayed period: 111.6x
SLNO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SLNO — Frequently Asked Questions
Quick answers to the most common questions about buying SLNO stock.
What is SLNO's P/E ratio?
Soleno Therapeutics, Inc. (SLNO) trailing twelve-month P/E ratio is N/A, based on TTM diluted EPS of N/A. The 5-year average P/E is 111.6x and the historical range spans 19.0x to 204.2x.
Is SLNO stock overvalued or undervalued?
SLNO current P/E: N/A. 5-year average P/E: 111.6x. Percentile: N/A.
Is SLNO stock expensive?
SLNO is fairly valued relative to its own history. The current P/E of N/A is near the 5-year average of 111.6x (N/A percentile of historical range).
What is SLNO's historical P/E range?
Over the past 5 years, SLNO's P/E ratio has ranged from 19.0x to 204.2x, with a median of 204.2x and an average of 111.6x. The current P/E of N/A places the stock at the N/A percentile of this range. Full historical data spans 2025–2026.
How does SLNO's P/E compare to the S&P 500?
SLNO current P/E: N/A. S&P 500 median P/E: 21.8x.
How does SLNO's valuation compare to Healthcare peers?
Soleno Therapeutics, Inc. P/E of N/A can be benchmarked against Healthcare peers in the comparison table on this page.
What is SLNO's PEG ratio?
SLNO PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SLNO's earnings yield?
SLNO earnings yield is N/A, the inverse of its N/A P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.